Gene Expression Immune Response In-Vivo Research 
Drug Discovery World
DECEMBER 15, 2022
As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific. Ideally, improvements to CRISPR and other platforms would achieve all three.
The Pharma Data
JULY 8, 2021
executive vice president of Research and Development at Amgen. Many patients with severe asthma have an inadequate response to currently available biologics and oral corticosteroids and thus fail to achieve asthma control.(2,6,9) Amgen (NASDAQ:AMGN) announced that the U.S. Reese, M.D., About Severe Asthma.
Expert insights. Personalized for you.
52 
Let's personalize your content